Subsequently, the single-arm phase II DESTINY-Gastric02 trial confirmed the safety and efficacy of T-DXd in the US and Europe for patients with HER2-positive GC/GEJC after a first-line trastuzumab-containing regimen [3]. The gene discussed is ERBB2; the disease is gastric cancer.